Use of PillCam ESO2 in Triaging Patients Present With Upper GIB
Primary Purpose
Upper Gastrointestinal Bleeding
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PillCam ESO2
Sponsored by
About this trial
This is an interventional screening trial for Upper Gastrointestinal Bleeding focused on measuring Gastrointestinal bleeding, emergency department, PillCam ESO2
Eligibility Criteria
Inclusion Criteria:
Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena
Exclusion Criteria:
- UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy,
- UGIB with fresh hematemesis requiring urgent endoscopy
- dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation,
- prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery.
- presence of an electromedical device (pacemaker or internal cardiac defibrillator),
- altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent.
- Allergy to Maxolon
- Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes
- Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Capsule group: PillCam ESO2
Standard group
Arm Description
Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
Perform standard esophagogastroduodenoscopy
Outcomes
Primary Outcome Measures
The number of patients requiring hospital admission
Patients with evidence of significant bleeding will be admitted to ward and receive early endoscopy (EGD)
Secondary Outcome Measures
Clinical rebleeding
Recurrent GI bleeding
Mortality
Death rate
Cost of management in different strategies
Cost of management in different strategies
Comparing the effectiveness of CE against Glasgow Blatchford score in identifying patients with UGIB that may require endoscopic intervention
Using Glasgow Blatchford score
Full Information
NCT ID
NCT02446678
First Posted
May 12, 2015
Last Updated
April 23, 2017
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT02446678
Brief Title
Use of PillCam ESO2 in Triaging Patients Present With Upper GIB
Official Title
The Use Of PillCam Esophagus In Triaging Patients Presented With Upper Gastrointestinal Bleeding
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
April 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background
Patients presented to hospital with coffee ground vomiting and black stool may not be actually having upper gastrointestinal bleeding (UGIB)
Hospital admission can be avoided if serious UGIB can be excluded
To date, the only useful tool to triage patient for hospital admission in UGIB is by using clinical score such as Rockall score or Blatchford score
These scores are cumbersome and only exclude the most benign cases, but they are not useful in differentiating those who needs intervention
In our pilot study, investigators found that capsule endoscopy can be used to identify patients with fresh blood and real coffee ground substance in the stomach and it is superior to nasogastric tube
Most of UGI lesions leading to bleeding can be diagnosed by capsule endoscopy
Objectives The current study is designed
to validate capsule endoscopy is an effective method in identifying patients with UGIB
to study whether the capsule endoscopy can reduce requirement of hospital admission in patients with suspected UGIB
to study if capsule endoscopy can help to identify patients with UGIB that may require urgent (within 24 hours) endoscopy and intervention
to study the cost-effectiveness of capsule endoscopy being used as a triaging tool in the management of UGIB
to compare the effectiveness of capsule endoscopy against Blatchford score in identifying patients with UGIB that may require endoscopic intervention.
Detailed Description
Hypothesis PillCam Esophagus is effective in identifying genuine UGIB and hence able to reduce hospital admission due to unsubstantiated UGIB cases
Methodology
Patients presented to the Accident & Emergency Department (A&ED) of the Prince of Wales Hospital Hong Kong with symptoms suggestive of UGIB will be recruited into this study
Patients will receive the following tests
Complete blood count
Coagulation profile
Renal and liver function tests
Hourly BP, Pulse up to 6 hours
Glasgow Blatchford score calculated on admission
Randomization
Capsule Group: Capsule Endoscopy (CE) by using PillCam Esophagus (PillCam ESO) OR
Standard group: Hospitalization and Standard of Care
The video in capsule endoscopy will be read by trained personnel who have undergone at least one hour lecture about realtime reviewing.
Legally a patient has to be signed off by a clinician within 6 hours. The finding of fresh blood or coffee ground will be documented. Upper GI pathology that may lead to bleeding will also be recorded.
Capsule Endoscopy (CE) After confirming patient has been fasted for at least 5 hours, the subject ingested the PillCam® ESO 2 (Given Imaging Ltd., Yoqneam, Israel) (PillCam ESO) using the Simplified Ingestion Procedure.
Thirty to sixty minutes prior to capsule ingestion, each subject received a single dose of intravenous Maxolon 10mg. Intravenous Maxolon, through its motilin receptor agonist effect, has been shown to promote gastric motility and improve visualization of the gastric mucosa at endoscopy. Moreover, use of Maxolon was thought to facilitate the capsule entering the duodenum.
Using the REAL time viewer, UGI tract images (esophagus to the second portion of the duodenum) were obtained in real time at the patient's bedside. The video images that are transmitted by the PillCam ESO 2 are displayed in real time on the tablet computer screen.
Each subject is also fitted with and wore the standard CE sensor array and data recorder so that a full-length CE video recording can be obtained for subsequent capsule workstation downloading and complete review.
Other demographic data and parameters for Blatchford score calculation will be collected. 10 ml of blood will be taken for routine blood checking. Patients will receive standard care according to EGD findings.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Gastrointestinal Bleeding
Keywords
Gastrointestinal bleeding, emergency department, PillCam ESO2
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Capsule group: PillCam ESO2
Arm Type
Active Comparator
Arm Description
Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
Arm Title
Standard group
Arm Type
No Intervention
Arm Description
Perform standard esophagogastroduodenoscopy
Intervention Type
Device
Intervention Name(s)
PillCam ESO2
Intervention Description
Capsule endoscopy
Primary Outcome Measure Information:
Title
The number of patients requiring hospital admission
Description
Patients with evidence of significant bleeding will be admitted to ward and receive early endoscopy (EGD)
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Clinical rebleeding
Description
Recurrent GI bleeding
Time Frame
30 days
Title
Mortality
Description
Death rate
Time Frame
30 days
Title
Cost of management in different strategies
Description
Cost of management in different strategies
Time Frame
One year
Title
Comparing the effectiveness of CE against Glasgow Blatchford score in identifying patients with UGIB that may require endoscopic intervention
Description
Using Glasgow Blatchford score
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena
Exclusion Criteria:
UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy,
UGIB with fresh hematemesis requiring urgent endoscopy
dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation,
prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery.
presence of an electromedical device (pacemaker or internal cardiac defibrillator),
altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent.
Allergy to Maxolon
Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes
Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jessica Y.L. Ching, MPH
Organizational Affiliation
Chinese University of Hong Kong
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27156655
Citation
Sung JJ, Tang RS, Ching JY, Rainer TH, Lau JY. Use of capsule endoscopy in the emergency department as a triage of patients with GI bleeding. Gastrointest Endosc. 2016 Dec;84(6):907-913. doi: 10.1016/j.gie.2016.04.043. Epub 2016 May 6.
Results Reference
derived
Learn more about this trial
Use of PillCam ESO2 in Triaging Patients Present With Upper GIB
We'll reach out to this number within 24 hrs